169 citations
,
September 2002 in “British journal of dermatology/British journal of dermatology, Supplement” This study reports that ZD1839 (Iressa), an anticancer drug, was associated with acneiform eruptions and hair growth abnormalities due to its inhibition of epidermal growth factor receptor signaling in the skin.
9 citations
,
September 2017 in “PubMed” This article discusses the common cutaneous side effects associated with EGFR inhibitors, emphasizing the importance of their management due to potential impacts on patients' quality of life and therapy response; no new empirical findings are reported.
April 2026 in “International Journal of Clinical Oncology” This review found that adding immune checkpoint inhibitors to cancer treatment regimens likely increases the incidence of specific drug-related skin toxicities in adult Asian patients, highlighting the need for careful monitoring and management strategies.
20 citations
,
July 2013 in “PLoS ONE” This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.
116 citations
,
December 2003 in “Acta Dermato Venereologica” This study reports that Iressa, an anti-cancer agent, commonly causes acneiform eruptions and xerosis as cutaneous side effects, similar to other agents targeting epidermal growth factor receptors.
